Phase II, multiple-dose study of anti-FcRn Antibody, Rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: Interim analysis

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: bc5b5dee7eb93a4661726706f2eedd9ff69c29b9
First added on: Feb 08, 2025